Friday, August 14, 2020
11:37 AM EST – Revive Therapeutics Ltd. : Announced that it has signed a Memorandum of Understanding (“MOU”) with Attwill Medical Solutions Sterilflow, LP to establish AMS as a resource for clinical packaging and distribution for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. “We are pleased to engage in formal discussions with Attwill Medical to assist us in the clinical packaging and distribution for our Phase 3 clinical study in COVID-19, as they have the resources and capabilities to execute on a number of activities that are critical to large-scale clinical studies,” said Michael Frank, CEO of Revive. Revive Therapeutics Ltd. (C.RVV) shares were up 8.93 percent at 0.305.
Stocks in Play: Revive Therapeutics Ltd., Fri, 14 Aug 2020 11:45:01 EST